Allergan Acquires QLT’s Aczone, Plans Fourth Quarter Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm pays $150 million for the topical acne treatment; QLT continues sale of assets.
You may also be interested in...
QLT Divests U.S. Business, Retains Wet AMD Treatment Visudyne
Following a strategic review of its assets, Canadian company divests its only other marketed product, prostate cancer drug Eligard, and lays off 115 employees.
QLT Asks FDA To Remove Blood Screening Requirement For Acne Treatment Aczone
Firm hopes results of Phase IV study convince FDA to approve a more marketable label for the topical acne treatment.
Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: